Bayer is also addressing some of the key challenges when it comes to healthcare AI development: In April of this year, the company announced its collaboration with Google Cloud. Bayer’s new AI Innovation Platform (AIIP), a cloud-based end-to-end software development platform designed to help streamline and accelerate the development, validation, and deployment of imaging-based AI/ ML (artificial intelligence/ machine learning) healthcare applications, and built on Google Cloud technology, is now ready for customer testing. AIIP aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products.
Focus on Connected Solutions
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Bayer will highlight its focus on creating smarter workflows. Bayer’s Cortenic™ Connectivity platform highlights the importance of data, connectivity, and interoperability across the continuum of care.
New clinical data for investigational contrast agent gadoquatrane – scientific paper awarded with the Kuo York Chynn Neuroradiology Research Award
Gadoquatrane, Bayer’s investigational gadolinium-based contrast agent for MRI, is currently being investigated in Phase III studies There will be two scientific RSNA sessions highlighting new data about the compound.
Gadoquatrane: Pharmacokinetics in healthy volunteers and patients with CNS lesions in combination with MR imaging in comparison to gadobutrol support dose selection for the novel tetrameric GBCA
Abstract No. M7-SSNR06-1, Session No. M7-SSNR06
The presentation will focus on highlights of a scientific paper which will be honored with the prestigious Kuo York Chynn Neuroradiology Research Award, being given for the top-rated Neuroradiology scientific paper for 2024. The award will be presented to Bayer during the RSNA annual meeting.
Gadoquatrane: Dose-response assessment in MR angiography for the novel tetrameric macrocyclic GBCA in comparison to gadobutrol or gadoterate in a non-clinical and a clinical setting
Abstract No. S3A-SPNR-16, Session No. S3A-SPNR
Collaboration with Subtle Medical
Bayer is announcing a further extension with the global med tech company Subtle Medical. The companies have agreed to move forward with the development of an investigational AI software in combination with an investigational lower dose of a contrast agent.
About AI in Radiology
The overall global medical imaging AI field, with sales of more than USD 734 million in 2023, is expected to continue growing dynamically. With an estimated compounded annual growth rate of 21 percent, the market is forecast to reach USD 2 billion by 2028. Innovation powered by AI is needed more than ever. Aging populations and changing lifestyles are leading to an increase in chronic conditions, such as cardiovascular disease and cancer. Consequently, the demand for medical imaging to detect diseases, guide treatment decisions and support therapy planning is growing. AI comes with the value proposition of potentially aiding diagnosis and increasing the throughput of radiological examinations.
